Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 prevalence and mortality in people with epilepsy: A nation-wide multicenter study

Alvaro Sanchez-Larsen a,1,⇑, Estefanía Conde-Blanco b,1, Alejandro Viloria-Alebesque c, Cristina Sánchez-Vizcaino Buendía d, Tatiana Espinosa Oltra d, Amanda Alvarez-Navai e, Angel Aledo-Serrano f, Raquel Martín-Garcia g, María E. Ramos-Araque h,i, Dulce Campos j, Gonzalo Valle-Peñaocaboj, Alicia Sierra-Gómez l, Pablo De Ceballos-Cerrajería k, Marta Agundez-Sarasola k, Mariam Khawaja l, Kevin G. Hampel m, Maria Serra-Martínez n, Clara Arbós-Barber n, Asier Gómez-Ibáñez o, Rafael Villino-Boquete p, Pablo Cabezudo-García q, Ignacio Rodríguez-Lavado q, Alessandro Principe r, David Sopelana-Barairy a

a Department of Neurology, Albacete University Hospital Complex, Albacete, Spain
b Epilepsy Program, Department of Neurology, Hospital Clinic de Barcelona, EpiCARE: European Reference Network for Epilepsy, Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
c Instituto de Investigación Sanitaria (IIS) Aragón, Department of Neurology, Hospital General de la Defensa, Zaragoza, Spain
d Department of Neurology, Cartagena University Hospital Complex, Murcia, Spain
e Department of Neurology, Ribera Povisa Hospital, Vigo, Spain
f Epilepsy Program, Department of Neurology, Ruber International Hospital, Madrid, Spain
g Department of Neurology, Puerta de Hierro University Hospital, Madrid, Spain
h Instituto de Investigación Biomédica de Salamanca (IBSAL), University Assistance Complex of Salamanca, Salamanca, Spain
i Department of Neurology, University Assistance Complex of Salamanca, Salamanca, Spain
j Department of Neurology, Valladolid University Clinical Hospital, Valladolid, Spain
k Department of Neurology, Urduliz Hospital, Bilbao, Spain
l Epilepsy Program, Department of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain
m Department of Neurology, La Fe University Hospital, Valencia, Spain
n Departamento de Neurología, Son Llàtzer University Hospital, Mallorca, Spain
o Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain
p Instituto de Investigación Biomédica de Málaga (IBIM), Department of Neurology, Regional University Hospital of Málaga, Málaga, Spain
q Epilepsy Unit, Department of Neurology, Hospital del Mar, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra (UPF), Barcelona, Spain

Article info

Article history:
Received 26 August 2021
Revised 1 October 2021
Accepted 2 October 2021
Available online 8 October 2021

Keywords:
COVID-19
Coronavirus, SARS-CoV-2
Prevalence
Epilepsy
Seizures

Abstract

Background: To assess the prevalence, severity, and mortality of COVID-19 in people with epilepsy (PWE) and evaluate seizure control in PWE during and after COVID-19.

Methods: Retrospective, observational, multicenter study conducted in 14 hospitals. Medical records of randomly selected PWE followed at neurology outpatient clinics were reviewed. Proportion of PWE with a positive test for SARS-CoV-2 during 2020 was calculated. Risk factors associated with COVID-19 and its morbimortality were evaluated.

Results: 2751 PWE were included, mean age 48.8 years (18–99), 72.4% had focal epilepsy, and 35% were drug-refractory. COVID-19 prevalence in PWE was 5.53%, while in the Spanish population was 4.26%. Proportion of admissions to hospital, ICU, and deaths in PWE were 17.1%, 2%, and 4.61% of COVID-19 cases, while in Spanish population were 10.81%, 0.95%, and 2.57%, respectively. A severe form of COVID-19 occurred in 11.8%; dyslipidemia, institutionalization at long-term care facilities, intellectual disability, and older age were associated risk factors. Older age, hypertension, dyslipidemia, cardiac disease, and institutionalization were associated with mortality from COVID-19. Seizure control was stable in 90.1% of PWE during acute COVID-19, while 8.6% reported an increase in seizure frequency. During post-COVID-19 follow-up, 4.6% reported seizure control worsening.

https://doi.org/10.1016/j.yebeh.2021.108379
1. Introduction

The current coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has challenged the world. Spain is one of the most affected countries since the pandemic outbreak, with one of the highest prevalence and mortality rates worldwide [1]. The scientific community has made a huge effort to identify the population at higher risk of suffering COVID-19 or a severe form of the disease. It is well known that age is the main factor associated with death due to COVID-19, but other risk factors have been proposed in different studies, sometimes with contradictory results. Whether some chronic conditions, such as epilepsy, are related in some manner to SARS-CoV-2 infection remains unclear.

The influence of the COVID-19 pandemic on people with epilepsy (PWE) is beyond question. Many studies have shown that a significant proportion of PWE (ranging from 8 to 31% depending on the series) have suffered a worsening in their epilepsy control, having an increase of seizure frequency during the pandemic [2–10]. Whether seizures, anti-seizure treatments, or epilepsy itself may be associated with any risk of immunosuppression, and thereby increase the risk to be infected by SARS-CoV-2 or having severe COVID-19 is under discussion [11,12]. Investigating this and assessing the specific morbidity and mortality of COVID-19 in PWE is of crucial importance to identify effective strategies to prevent infection and to reduce its impact. However, thus far, only a couple of studies have systematically evaluated the incidence, prevalence, and death rates of COVID-19 in patients with epilepsy [13,14]. The evidence suggests that the risk of having COVID-19 was higher in PWE and that the case-fatality rate was higher in those patients with active epilepsy than in the rest of the hospitalized patients with severe COVID-19. Though of high relevance, these results studied relatively small samples and require further scientific support.

This study aimed to assess the prevalence of confirmed cases of SARS-CoV-2 infection in PWE. The severity of COVID-19, the associated morbidity and mortality in PWE, as well as the factors associated with the infection or its severity were also analyzed. Likewise, seizure control in PWE during and after COVID-19 infection was evaluated. The results were contrasted with the official data of people infected by SARS-CoV-2 in Spain during the study period, given by the Health Ministry’s national records [15,16].

2. Methods

2.1. Design and settings

A retrospective, observational, multicenter study was conducted in 14 hospitals distributed throughout the country. We included data between January 1, 2020, and December 31, 2020.

2.2. Study population

The study population were patients over 18 years old diagnosed with epilepsy according to the current criteria [17]. Patients were excluded if the diagnosis of epilepsy could not be confirmed and if there were any doubts between epilepsy or other nonepileptic paroxysmal disorders. Also, patients who met the criteria of resolved epilepsy [17] were excluded. In addition, patients who had died before March 2020 (when the COVID-19 pandemic reached Spain) were excluded. Subjects were selected randomly among the study population previously described. To obtain the randomized sample, each center collected all PWE followed up in their neurology outpatient clinics (N) and performed a random selection of N by creating a table of random numbers from 1 to N and selecting the first 200 numbers generated. Demographic and clinical characteristics of PWE were described: age, sex, intellectual disability, type of epilepsy (according to the current ILAE classifications of seizures and epilepsies [18,19]), etiology of epilepsy, active epilepsy [20], drug-resistant epilepsy, and history of epilepsy surgery.

2.3. Variables collected

The primary outcome of this study was the prevalence of SARS-CoV-2 infection in PWE in 2020, defined as the proportion of PWE with at least one positive test demonstrating the presence of SARS-CoV-2 in the nasopharynx (by real-time reverse transcription-polymerase chain reaction [rt-PCR] and/or antigenic detection test [AT]) or the presence of SARS-CoV-2 specific antibodies in serum (by positive Enzyme-Linked ImmunoSorbent Assay [ELISA] or rapid antibody test [RAbT]), among the total sample of PWE. A secondary outcome was the severity of COVID-19, classified as asymptomatic, mild, or severe infection according to the 2007 Infectious Diseases Society of America/American Thoracic Society criteria [21]. Admissions to the emergency department, hospital, or intensive care unit (ICU) and fatality rate (proportion of deaths related to COVID-19 among those infected) were also recorded. The risk of progression to severe COVID-19 was evaluated using the CALL score [22]. We evaluated several comorbidities of COVID-19 patients and their relationship with infection severity and death were explored. Finally, seizure control during and after COVID-19 infection was divided into worsening (increase of seizure frequency > 50% compared with the pre-COVID-19 period [mean per month during previous three months]), stability, or improvement (decrease of seizure frequency > 50% compared with the pre-COVID-19 period), considering the COVID-19 period as the first 14 days of the infection. All variables were collected by reviewing the hospital and primary care medical records and/or face-to-face or telephone consultation with the patients by neurologists and neurology residents.

The results were compared with the proportion of positive rt-PCR, AT, ELISA, and RAbT for SARS-CoV-2 within the national general population, published by the Spanish Health Ministry during the same period [15,16]. Also, the proportion of admissions to hospital, to ICU, and proportion of deaths due to COVID-19 reported by the Ministry were compared with those found in our series during the same period [15].

2.4. Estimation of the sample size

The size of the sample was calculated based on a prior epidemiologic study in our country [13] that reported a cumulated incidence of COVID-19 of 0.0119 and 0.005 in PWE and general population, respectively. Assuming an alpha risk of 0.05, a power (beta) of 80%, and a percentage of data loss of 20%, the sample should be at least 2466 PWE. Assuming the possibility that the ref-
ferences used do not represent our population of PWE, we decided to increase the sample up to 2750 patients.

2.5. Statistical analysis

The statistical analysis was performed using Stata/IC 14.2 (StataCorp LLC). A descriptive analysis of the variables collected was performed: the qualitative variables were expressed as a percentage and the quantitative variables using mean ± standard deviation (SD) or median-interquartile range (IQR) whether they had a normal distribution. Prevalence of COVID-19 and mortality due to COVID-19 were calculated as the proportion of positive tests for SARS-CoV-2 and deaths due to COVID-19 among the total sample of PWE and were compared with the national prevalence and mortality during the same period. Similarly, admissions to hospital and ICU due to COVID-19 were calculated as the proportion of these events among the total sample of PWE and compared with the national data. An analysis of the main factors associated with contracting and dying from COVID-19 was performed: the ratios were compared using the $X^2$ test or Fisher exact test, quantitative variables were compared using Student’s t test or the U-Mann–Whitney test when appropriate. Finally, univariate and multivariate analyses using logistic regression were performed following biological plausibility, based on current scientific knowledge regarding the etiology and mechanisms of COVID-19. The confidence intervals (CI) and odds ratios (OR) were calculated. In all cases, p-values less than 0.05 were considered statistically significant. To assess the fit of the logistic regression model we used the Hosmer-Lemeshow goodness-of-fit test.

2.6. Ethics

This study received approval from the ethical standards committee of the Complejo Hospitalario Universitario de Albacete (identifier: 2021/01/026). A waiver of written informed consent was obtained since all data were collected retrospectively and anonymously.

3. Results

3.1. Demographic characteristics of PWE

We included 2751 PWE from 14 hospitals across the country. The mean age was 48.8 years, range 18–99 (Fig. 1), 50.8% were
men. According to epilepsy type, 71.5% had focal epilepsy, 23.1% generalized epilepsy (68.4% of whom had idiopathic generalized epilepsy) and 5.4% had unknown epilepsy. The most frequent known etiologies were vascular (11.2%), malformation of cortical development (7.2%), and tumoral (6.1%). The 66.8% had active epilepsy, 29.4% were drug-refractory, and 6.4% had a history of epilepsy surgery. More epidemiological details are shown in Table 1.

3.2. COVID-19 prevalence and risk factors of infection

COVID-19 prevalence in our sample was 5.53% (95% CI 4.73–6.44), 152 out of 2751 PWE tested positive for SARS-CoV-2, with no reinfection cases (Fig. 2). Almost half of the patients (42.1%) tested positive during the second wave in Spain (October–December), compared to 30.9% during the first wave (March–May) (Fig. 1, Table 2). Seventy-two percent of COVID-19 patients had active epilepsy, almost half of them (48%) were taking 2 or more anti-seizure medications (ASMs) and 20.4% of patients infected had an intellectual disability. Patients with intellectual disability were more likely to contract COVID-19 (OR 10.11, 95% CI 1.24–82.14, p = 0.030), institutionalization at long-term care facilities (OR 19.49, 95% CI 2.95–128.92, p = 0.002), and dyslipidemia (OR 7.45, 95% CI 1.46–38.34, p = 0.016). Hypertension (4.53, 95% CI 1.65–12.51, p = 0.004), cardiac disorders (8.84, 95% CI 2.76–28.31, p < 0.0001), respiratory disorders (7.88, 95% CI 2.34–26.50, p = 0.001), and other neurological diseases (3.97, 95% CI 1.43–11, p = 0.008) were statistically significant in the univariate analysis but not in the multivariate one, as shown in Table 3.

Overall, 25% of PWE with COVID-19 consulted in an Emergency Department (ED), 17.1% were admitted to hospital, and only 2% were transferred to an ICU (Table 2). The case-fatality rate was 4.61% (95% CI 2.19–9.42): seven patients died from COVID-19.

### Table 1

| Demographic characteristics of population of people with epilepsy. | COVID-19 – n (%) | COVID-19 + n (%) | p value |
|---------------------------------------------------------------|------------------|------------------|---------|
| **Total**                                                     | 2599 (94.47%)    | 152 (5.53%)      | 0.0505  |
| **Sex**                                                       |                  |                  |         |
| Man                                                          | 1397 (50.8%)     | 73 (48%)         |         |
| Woman                                                        | 1354 (49.2%)     | 79 (52%)         |         |
| **Age**                                                       |                  |                  | 0.456   |
| Mean                                                         | 48.8             | 49.9             |         |
| SD                                                           | 18.8             | 20.7             |         |
| Range                                                        | 18–99            | 18–96            |         |
| **Epilepsy type**                                            |                  |                  | >0.999  |
| Generalized                                                  |                  |                  |         |
| IGE with GTCS only                                           | 259 (43.4%)      | 10 (33.3%)       |         |
| JME                                                          | 106 (18.7%)      | 8 (26.7%)        |         |
| Juvenile absence                                             | 42 (7.4%)        | 3 (10%)          |         |
| Childhood absence                                            | 19 (3.3%)        |                  |         |
| Epileptic encephalopathy                                     | 30 (5.0%)        | 3 (10%)          |         |
| Other genetic generalized epilepsies*                        | 80 (13.4%)       | 4 (13.3%)        |         |
| Others                                                       | 50 (8.4%)        | 2 (6.7%)         |         |
| **Focal**                                                    |                  |                  | 0.854   |
| Frontal                                                      | 1966 (71.5%)     | 110 (72.4%)      |         |
| Temporal                                                     | 734 (37.2%)      | 32 (28.8%)       |         |
| Posterior quadrant                                           | 226 (11.5%)      | 11 (9.9%)        |         |
| Unknown                                                      | 617 (31.3%)      | 46 (41.4%)       |         |
| **Unknown**                                                  | 149 (5.5%)       | 7 (4.6%)         | 0.853   |
| **Etiology**                                                 |                  |                  | 0.096   |
| Genetic                                                      | 144 (5.2%)       | 6 (3.9%)         | 0.576   |
| MCD                                                          | 198 (7.2%)       | 7 (4.6%)         | 0.257   |
| Perinatal                                                    | 114 (4.1%)       | 10 (6.6%)        | 0.138   |
| Vascular                                                     | 307 (11.2%)      | 15 (9.9%)        | 0.692   |
| Infectious                                                   | 70 (2.5%)        | 6 (3.9%)         | 0.280   |
| TBI                                                          | 125 (4.5%)       | 3 (2%)           | 0.157   |
| Autoimmune                                                   | 35 (1.3%)        | 3 (2%)           | 0.440   |
| Tumoral                                                      | 169 (6.1%)       | 5 (3.3%)         | 0.163   |
| Others                                                       | 203 (7.4%)       | 14 (9.2%)        | 0.341   |
| IGE                                                          | 435 (15.8%)      | 21 (13.8%)       | 0.568   |
| Intellectual disability                                      |                  |                  |         |
| No                                                           | 2354 (85.6%)     | 121 (79.6%)      | 0.042*  |
| Yes                                                          | 397 (14.4%)      | 31 (20.4%)       |         |
| **Active epilepsy**                                          |                  |                  | 0.156   |
| No                                                           | 871 (33.3%)      | 42 (27.6%)       |         |
| Yes                                                          | 1728 (66.6%)     | 110 (72.4%)      |         |
| **Drug-refractory epilepsy**                                 |                  |                  | 0.142   |
| No                                                           | 1844 (70.9%)     | 99 (65.1%)       |         |
| Yes                                                          | 755 (29.1%)      | 53 (34.9%)       |         |
| **Epilepsy surgery**                                         |                  |                  | 0.865   |
| No                                                           | 2433 (93.6%)     | 142 (93.4%)      |         |
| Yes                                                          | 166 (6.4%)       | 10 (6.6%)        |         |

Significant values were marked with *

COVID-19: coronavirus disease 2019. GTCS: generalized tonic-clonic seizure; IGE: idiopathic generalized epilepsy; JME: juvenile myoclonic epilepsy; MCD: malformation of cortical development; PWE: people with epilepsy; TBI: traumatic brain injury.

* Including generalized epilepsies with genetic confirmation different than IGE and epileptic encephalopathies
Older age (OR 1.21, 95% CI 1.06–1.38, p = 0.004), hypertension (OR 8.16, 95% CI 1.51–43.98, p = 0.015), dyslipidemia (OR 12, 95% CI 2.20–65.39, p = 0.004), cardiac disease (OR 7.61, 95% CI 1.53–37.78, p = 0.013), and institutionalization at long-term care facilities (OR 33, 95% CI 3.85–292.36, p = 0.001) were all associated with mortality attributable to COVID-19 in the univariate analysis (Table 4). No association was found between intellectual disability and mortality (p = 0.684). Multivariate analysis was not appropriate due to the low sample size for the number of variables to test.

The mean age of deceased patients was 85.6 (SD 10.8) years, 6 of 7 patients were institutionalized in residencies. Noteworthy, 6 out of 7 patients were admitted to the hospital but none of them was transferred to the ICU. Mortality was higher among those patients who contracted COVID-19 during the first wave: 5 out of 7 deceased patients got infected from March to May 2020.

3.4. Seizure control during COVID-19 infection

According to control of epilepsy in patients with COVID-19, 47% were taking one ASM, 35% were drug-refractory. The most frequent ASMs used were levetiracetam (36.2%), valproate (26.3%), lacosamide (19.7%), and lamotrigine (19.1%). Basal seizure control in COVID-19 patients is described in Table 2. During the course of the infection, nearly all (90.1%) remained with the same seizure frequency, 6 of whom returned to their baseline during the convalescence period (Table 2). Patients had a mean post-COVID-19 follow-up time of 4.6 months (SD 3.19 months) and no relevant change of seizure frequency was found.

3.5. Spanish demographics and COVID-19 epidemiological results

The total population in Spain in 2020 was 47,332,614 inhabitants [23]; the Spanish Health Ministry reported 2,028,472 cases of SARS-CoV-2 infection (almost all through rt-PCR and RAbT) during 2020 [15], with a prevalence of 4.26%. When considering only the population older than 19 years, in Spain there were 38,053,467 inhabitants in 2020, with a mean age of 51.2 years [23], and the Spanish Health Ministry reported 1,699,649 cases of SARS-CoV-2 infection during 2020 [15]. Therefore, 4.47% of the Spanish population above 19 years of age tested positive for SARS-CoV-2 during 2020. The comparison between the prevalence of each participating center and that of their respective city and region is represented in Fig. 3. The proportion of admissions to hospital, ICU, and deaths because of COVID-19 in 2020 in Spain were 10.81%, 0.95%, and 2.57% of COVID-19 cases, respectively. Excluding people under 19 years of age, the proportion of hospitalizations due to COVID-19 increased to 12.76% of patients, 1.11% cases were admitted to ICU, and 3.06% of cases died during 2020 [15]. On the other side, the nationwide seroepidemiological study reported a prevalence of SARS-CoV-2 infection in the Spanish population of 9.9% of the sample studied as of December 15, 2020 [16]. Fig. 3 represents the reported prevalence per city and region.
COVID-19 outbreak [24–25]. To date, only a few studies aimed to solve this issue [13,14,26], with contradictory results and some of them important biases. Our study presents data collected by each participating center, hindering the comparison. On the other hand, intellectual disabilities [39–40]. However, this higher prevalence of neurological conditions have not been independently associated with a predisposition to suffer COVID-19 [30]; however, there is evidence that the immune response can be impaired in people with neurological disorders. It is known that a direct immune modulation is exerted by the central nervous system (CNS) through the vagus-splenic reflex, referred to as the cholinergic anti-inflammatory pathway [31,32]. Experimental studies demonstrated that brain lesions in some autonomic regulatory regions prevent immune activation depending on T-cell response [33–34], supporting that parasympathetic and sympathetic drives mediate immune adaptive responses. Ictal and interictal autonomic disturbances can occur in PWE with a possible impact on immune response [35–38]. Moreover, some data suggest that ASM can directly affect both humoral and cellular immunity, modifying the synthesis and expression of cytokines [12], but the mechanisms are not fully understood and other intercurrent factors may act as confounders.

4.2. Immune response in PWE

In our cohort of PWE, SARS-CoV-2 infection was more likely for patients with active epilepsy (72.4% vs 66.5%) and intellectual disability (20.4% vs 14.4%), being significantly associated only with the latter one. So far, neurological conditions have not been independently associated with a predisposition to suffer COVID-19 [30]; however, there is evidence that the immune response can be impaired in people with neurological disorders. It is known that a direct immune modulation is exerted by the central nervous system (CNS) through the vagus-splenic reflex, referred to as the cholinergic anti-inflammatory pathway [31,32]. Experimental studies demonstrated that brain lesions in some autonomic regulatory regions prevent immune activation depending on T-cell response [33–34], supporting that parasympathetic and sympathetic drives mediate immune adaptive responses. Ictal and interictal autonomic disturbances can occur in PWE with a possible impact on immune response [35–38]. Moreover, some data suggest that ASM can directly affect both humoral and cellular immunity, modifying the synthesis and expression of cytokines [12], but the mechanisms are not fully understood and other intercurrent factors may act as confounders.

4.3. Risk factors for severe COVID-19 and mortality in PWE

In our cohort of PWE, the proportion of patients who needed medical assistance because of COVID-19 was high. A large population-based study reported that epilepsy was a risk factor for hospital admission and mortality due to COVID-19 in adults [25]. Other studies reported a high proportion of severe COVID-19 courses and deaths caused by the infection in PWE [4,13,39,40]. However, these studies were limited to institutionalized PWE or hospitalized patients during the first wave of the pandemic, so selection and severity biases may exist. The 11.9% of severe infections in PWE outlined in our study is close to the 10.2% found in a literature review [30], and clearly below the reported for cerebrovascular diseases (19.3%), dementias (22.2%), or multiple sclerosis (39.4%) [30]. It should be considered that epilepsy can have many causes and associations that can act as risk factors for developing severe respiratory or systemic infections. Some comorbidities such as older age, hypertension, diabetes, dyslipidemia, cardiac, and respiratory pathologies are demonstrated risk factors for severe COVID-19 [25,41], although most of them are also risk factors for epilepsy [42]. It should be noted that the prevalence of these comorbidities was not known in the national population, hindering the comparison. On the other hand, intellectual disability acted as a risk factor for contracting COVID-19 and for having a severe course of the disease, though it was not associated with higher mortality. Epidemiological evaluations of long-term care facilities for PWE revealed a COVID-19 prevalence of 10% to 63% of their residents, the majority of whom had intellectual disabilities [39–40]. However, this higher prevalence of COVID-19 is probably related to the facility of the virus to spread among the institution residents rather than with their cognitive comorbidities. Mortality due to COVID-19 in our study affected mainly elderly patients, institutionalized in nursing homes, and with other comorbidities, so that epilepsy did not appear to be the main risk factor for death.
4.4. Influence of COVID-19 infection in epilepsy control

Neurological symptoms are usual during the COVID-19 course [43–44]. However, although electroencephalographic abnormalities have been reported in high percentages of patients with SARS-CoV-2 infection [45–46], seizures are very infrequent in these cases [43,44,47–49]. Besides that, during the first months of the pandemic, seizure control has worsened in a significant proportion of PWE [2–10]. In most cases, this decumption was not directly related to SARS-CoV-2 infection, but attributable to different pandemic-related factors such as psychological distress, sleep disorders, or difficulties obtaining ASM. Our study evaluated the seizure control of a broad cohort of PWE during the acute phase of COVID-19, and the results point in the same direction, with a few (8.6%) of our COVID-19 patients reporting a significant worsening of their seizures during the infection. Therefore, SARS-CoV-2 infection has little impact on seizure control in PWE, which is striking, since fever and systemic infections are well-known seizure triggers [50]. Also valuable, we conducted a long-term post-infection follow-up in a large number of patients. Indeed, half of the patients in whom seizure control worsened during COVID-19 returned to baseline at the convalescence phase, only 4.6% maintained an increase in seizure frequency after the infection, and when considering a long-term follow-up, the vast majority of our cohort were stable in their epilepsy control.

4.5. Study limitations

Despite the high number of subjects included in the study and the adequate potency in order to calculate COVID-19 prevalence in PWE, this is a retrospective study and the association of the infection and its course with the analyzed risk factors must be treated with caution, since direct causality cannot be properly inferred. In addition, other clinical or socio-demographic factors not assessed in the study may have influenced the risk of contracting COVID-19 or determining its morbimortality. The circumstances of the infection could not be investigated, and seizure count was based in many cases on patients’ subjective recall of the infection period. Finally, socio-demographic characteristics of the reference group could not be evaluated, limiting the comparison of these data with our results.

### Table 3
Univariate and multivariate analyses of risk factors for severe COVID-19 infection.

| Variable | Univariate analysis | Multivariate analysis |
|----------|---------------------|-----------------------|
|          | OR  | CI    | p     | OR  | CI    | p     |
| Age      | 1.07 | 1.04–1.11 | <0.0001* | 1.09 | 1.03–1.17 | 0.005* |
| Sex (male) | 0.91 | 0.34–2.44 | 0.858 | -   | -     | -     |
| Intellectual disability | 2.92 | 1.03–8.30 | 0.045* | 10.11 | 1.24–82.14 | 0.030* |
| Epilepsy type | 2.16 | 0.92–5.08 | 0.076 | -   | -     | -     |
| Generalized | 0.93 | 0.29–3.09 | 0.931 | -   | -     | -     |
| Focal     | 0.99 | 0.33–2.98 | 0.988 | -   | -     | -     |
| Unknown   | 1.25 | 0.14–11.06 | 0.838 | -   | -     | -     |
| Etiology  | Unknown | Reference | - | - | - | - |
| Genetic   | 11.40 | 1.8–71.9 | 0.010* | 7.69 | 0.58–102.1 | 0.122 |
| MCD       | -   | -     | -     | -   | -     | -     |
| Perinatal | 1.26 | 0.13–12.10 | 0.838 | -   | -     | -     |
| Vascular  | 7.6  | 1.91–30.19 | 0.004* | 1.14 | 0.11–12.4 | 0.911 |
| Infectious | 2.28 | 0.22–23.50 | 0.489 | -   | -     | -     |
| TBI       | -   | -     | -     | -   | -     | -     |
| Autoimmune| -   | -     | -     | -   | -     | -     |
| Tumoral   | -   | -     | -     | -   | -     | -     |
| Others    | 1.90 | 0.33–10.98 | 0.98 | -   | -     | -     |
| IGE       | -   | -     | -     | -   | -     | -     |
| Active epilepsy | 0.55 | 0.20–1.54 | 0.260 | -   | -     | -     |
| Drug-refractory epilepsy | 0.49 | 0.15–1.59 | 0.238 | -   | -     | -     |
| Hypertension | 4.53 | 1.65–12.51 | 0.004* | 0.29 | 0.05–1.86 | 0.194 |
| Diabetes mellitus | 2.03 | 0.51–8.03 | 0.311 | -   | -     | -     |
| Dyslipidemia | 9.51 | 3.28–27.58 | <0.0001* | 7.45 | 1.46–36.34 | 0.016* |
| Cardiac disorder | 8.84 | 2.76–28.31 | <0.0001* | 2.41 | 0.48–12.16 | 0.287 |
| Respiratory disorder | 7.88 | 2.34–26.50 | 0.001* | 4.56 | 0.71–29.13 | 0.287 |
| Autoimmune disorder | 1.91 | 0.20–18.11 | 0.572 | -   | -     | -     |
| Neurological comorbidity | 3.97 | 1.43–11.00 | 0.008* | 1.28 | 0.30–5.37 | 0.738 |

Significant values were marked with *.

IGE: idiopathic generalized epilepsy; MCD: malformation of cortical development; TBI: traumatic brain injury.

### Table 4
Univariate analysis of risk factors for death due to COVID-19.

| Variable | Univariate analysis |
|----------|---------------------|
|          | OR  | CI    | p     |
| Age      | 1.21 | 1.06–1.38 | 0.004* |
| Sex (male) | 0.35 | 0.07–1.88 | 0.223 |
| Intellectual disability | 0.64 | 0.07–5.51 | 0.684 |
| Epilepsy type | 1.04 | 0.25–5.73 | 0.82 |
| Etiology     | 1.04 | 0.86–1.26 | 0.66 |
| Active epilepsy | 2.36 | 0.28–20.26 | 0.432 |
| Institutionalized | 33.54 | 3.84–292.36 | 0.001* |
| Hypertension | 8.16 | 1.51–43.98 | 0.015* |
| Diabetes mellitus | -   | -     | -     |
| Dyslipidemia | 12  | 2.20–65.39 | 0.004* |
| Cardiac disorder | 7.61 | 1.53–37.78 | 0.013* |
| Respiratory disorder | 4.43 | 0.77–25.33 | 0.094 |
| Autoimmune disorder | -   | -     | -     |
| Neurological comorbidity | 2.96 | 0.64–13.79 | 0.166 |
5. Conclusion

COVID-19 was moderately prevalent in PWE. One out of 5 patients required medical attention and 4.6% died due to COVID-19. Older age, dyslipidemia, intellectual disability, and institutionalization at long-term care facilities, were significant risk factors associated with severe COVID-19, and for mortality, older age, hypertension, dyslipidemia, cardiac disease, and institutionalization at long-term care facilities were significantly associated. Seizure control remained stable on most of the PWE who contracted COVID-19 both during the acute phase and throughout long-term follow-up after the infection, suggesting that SARS-CoV-2 infection has little impact on seizure control in PWE.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

In memory of all the people in our country who have suffered the consequences of COVID-19.

References

[1] Johns Hopkins University and Medicine. COVID-19 Map. Johns Hopkins Coronavirus Resource Centre, https://coronavirus.jhu.edu/map.html [accessed 20 February 2021].
[2] Aledo-Serrano Á, Mingorance A, Jiménez-Huete A, Toledano R, García-Morales I, Anciones C, et al. Genetic epilepsies and COVID-19 pandemic: lessons from the caregiver perspective. Epilepsia 2020;61(6):1312–4. https://doi.org/10.1111/epi.v61.610.1111/epi.16537.
[3] Conde Blanco E, Manzanares I, Centeno M, Khawaja M, Betrán O, Donaire A, et al. Epilepsy and lockdown: a survey of patients normally attending a Spanish centre. Acta Neurol Scand 2021;143(2):206–9. https://doi.org/10.1111/ane.v143.210.1111/ane.13354.
[4] Fonseca E, Quintana M, Lallana S, Luis Restrepo J, Abraira L, Santamarina E, et al. Epilepsy in time of COVID-19: a survey-based study. Acta Neurol Scand 2020;142(6):545–54. https://doi.org/10.1111/ane.v142.610.1111/ane.13335.
[5] Sanchez-Larsen A, Gonzalez-Villar E, Diaz-Maroto I, Layos-Romero A, Martinez-Martín Á, Alcahut-Rodriguez C, et al. Influence of the COVID-19
